Perspective from Muhammad Afzal, MBBS
Perspective from Raj Khandwalla, MD
March 16, 2020
3 min read

Handheld device shows promise for detecting atrial fibrillation

Perspective from Muhammad Afzal, MBBS
Perspective from Raj Khandwalla, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

A screening tool demonstrated high sensitivity for detecting atrial fibrillation among more than 1,500 adults in Brazil who were referred for an echocardiogram, according to a study published in Heart.

Researchers said MyDiagnostick (Applied Biomedical Systems) is a handheld, rod-shaped metal device with sensible electrodes on both ends and an indicator light that alerts physicians to atrial fibrillation. The single-lead device is more than 10 times cheaper than a standard smartwatch, they added. A company representative told Healio Primary Care that MyDiagnostick costs 550 euros (or approximately $604) plus shipping and administrative costs.

A previously published report in PLoS One indicated that atrial fibrillation is the most common sustained heart arrhythmia, associated with an approximately fivefold increase in stroke. More than 46 million patients worldwide have atrial fibrillation, and there are nearly 4 million new cases diagnosed each year. The PLoS One report also indicated that both U.S. and European guidelines recommend diagnosing atrial fibrillation based on a 12-lead ECG. However, the 12-lead ECG use for atrial fibrillation in primary care has not been proven cost-effective, regardless of a patient’s risk for the condition.

In the new study, Adriana C. Diamantino, MD, of the Hospital das Clinicas da Universidade Federal de Minas Gerais in Brazil, and colleagues wrote that evidence shows smartwatches have good accuracy in diagnosing atrial fibrillation. However, because smartwatches are cost-prohibitive for some patients, they wanted to determine the accuracy of MyDiagnostick.

Diamantino AC, et al. Heart. 2020;doi:10.1136/heartjnl-2019.316277.

Diamantino and colleagues performed clinical evaluation of 1,518 patients (mean age, 58 years; 66% women), who were stratified by CV risk. The authors indicated that the hand-held device detected a high risk for atrial fibrillation in 12.6% of the cohort, intermediate risk in 6.1% of the cohort and a low risk in 2.2% of the cohort. When an echocardiogram was used to verify risk, a positive indication of atrial fibrillation via the device was independently associated with heart disease (OR = 3.9; 95% CI, 2.1-7.2). The device also had sensitivity of 90.2% (95% CI, 77-97.3) and specificity of 84% (95% CI, 79.3-88) for detecting atrial fibrillation vs. a 12-lead ECG.

The results suggest that MyDiagnostick “may be a promising screening tool, for both early atrial fibrillation diagnosis and prioritization for cardiology referrals in under-resourced health systems,” Diamantino and colleagues wrote. – by Janel Miller


Diamantino AC, et al. Heart. 2020;doi:10.1136/heartjnl-2019.316277.

Hill NR, et al. 2019;doi:10.1371/journal.pone.0224582.

Disclosures: The authors report no relevant financial disclosures.